Matthew Gantz

Matthew Gantz is President and Chief Executive Officer of Castle Creek Biosciences, Inc., and a member of the company’s Board of Directors. An accomplished life sciences executive with more than 25 years of experience in the specialty biopharmaceutical and medical device industries, Mr. Gantz previously served as Chief Executive Officer of OxThera AB.

Prior to joining OxThera AB, Mr. Gantz served in roles of increasing responsibility with BTG plc (BTG), a leading specialty healthcare company, culminating in his appointment to Executive Vice President, US, of BTG Inc. Previously, Mr. Gantz founded and served as Chief Executive Officer of Acureon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on hospital areas of infectious diseases, transplant and intensive critical care. Prior to Acureon, he was President and Chief Executive Officer of Hydra Biosciences, Inc., a privately held biotechnology company developing novel, ion channel medicines to treat pain, inflammation and cardiovascular disease. Earlier in his career, Mr. Gantz held various senior executive positions with Chiron Corporation, PathoGenesis Corporation and Abbott Laboratories.

Mr. Gantz is currently a board member of Swedish Orphan Biovitrum AB, a publicly traded, international rare disease company, and the Marine Corps Scholarship Foundation, a not for profit organization that provides scholarships for the children of Marines to pursue secondary education.

He received his B.A. in history from Princeton University, his M.B.A. from Harvard Business School and served as an infantry officer in the U.S. Marine Corps.